Sonnet BioTherapeutics Holdings (SONN) said Wednesday it has received a patent from the US Patent and Trademark Office for its SON-1411 and SON-1400 immunotherapeutic drug candidates.
The patent, which covers a variant of recombinant human interleukin-18 contained in the two drug candidates, is effective until June 2044, Sonnet said.
SON-1411, a bifunctional fusion protein, and SON-1400, a monofunctional fusion protein, are linked to Sonnet's fully human albumin binding platform, the company said.
Shares of Sonnet rose more than 119% in early Wednesday trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。